172 related articles for article (PubMed ID: 16036792)
1. Depressive symptoms, quality of life, and neuropsychological performance in HIV/AIDS: the impact of gender and injection drug use.
Wisniewski AB; Apel S; Selnes OA; Nath A; McArthur JC; Dobs AS
J Neurovirol; 2005 Apr; 11(2):138-43. PubMed ID: 16036792
[TBL] [Abstract][Full Text] [Related]
2. HIV infection and risk, prevention, and testing behaviors among injecting drug users -- National HIV Behavioral Surveillance System, 20 U.S. cities, 2009.
Broz D; Wejnert C; Pham HT; DiNenno E; Heffelfinger JD; Cribbin M; Krishna N; Teshale EH; Paz-Bailey G;
MMWR Surveill Summ; 2014 Jul; 63(6):1-51. PubMed ID: 24990587
[TBL] [Abstract][Full Text] [Related]
3. Streets, drugs, and the economy of sex in the age of AIDS.
Weeks MR; Grier M; Romero-Daza N; Puglisi-Vasquez MJ; Singer M
Women Health; 1998; 27(1-2):205-29. PubMed ID: 9640643
[TBL] [Abstract][Full Text] [Related]
4. Gender differences in clinical manifestations before AIDS diagnosis among injecting drug users.
Spijkerman IJ; Langendam MW; van Ameijden EJ; Coutinho RA; van den Hoek A
Eur J Epidemiol; 1998 Apr; 14(3):213-8. PubMed ID: 9663511
[TBL] [Abstract][Full Text] [Related]
5. Gender differences in HIV risk behaviours among intravenous drug users in Catalonia, Spain.
Folch C; Casabona J; Espelt A; Majó X; Meroño M; Gonzalez V; Brugal MT;
Gac Sanit; 2013; 27(4):338-43. PubMed ID: 23578527
[TBL] [Abstract][Full Text] [Related]
6. Cortisol levels and depression in men and women using heroin and cocaine.
Wisniewski AB; Brown TT; John M; Cofranceso J; Golub ET; Ricketts EP; Wand G; Dobs AS
Psychoneuroendocrinology; 2006 Feb; 31(2):250-5. PubMed ID: 16157457
[TBL] [Abstract][Full Text] [Related]
7. Gender differences in illicit substance use among middle-aged drug users with or at risk for HIV infection.
Hartel DM; Schoenbaum EE; Lo Y; Klein RS
Clin Infect Dis; 2006 Aug; 43(4):525-31. PubMed ID: 16838244
[TBL] [Abstract][Full Text] [Related]
8. HIV Risk, prevention, and testing behaviors among heterosexuals at increased risk for HIV infection--National HIV Behavioral Surveillance System, 21 U.S. cities, 2010.
Sionean C; Le BC; Hageman K; Oster AM; Wejnert C; Hess KL; Paz-Bailey G; ;
MMWR Surveill Summ; 2014 Dec; 63(14):1-39. PubMed ID: 25522191
[TBL] [Abstract][Full Text] [Related]
9. Safe sex? Misconceptions, gender differences and barriers among injection drug users: a focus group approach.
Weiss SH; Weston CB; Quirinale J
AIDS Educ Prev; 1993; 5(4):279-93. PubMed ID: 8297708
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life of HIV-infected intravenous drug users.
Surah S; Adams R; Townsend L; Reynolds I; Kinahan JC; Keating S; Mulcahy F; Keenan E; Barry M; Lyons F
Int J STD AIDS; 2013 Nov; 24(11):867-74. PubMed ID: 23970601
[TBL] [Abstract][Full Text] [Related]
11. HIV risk, prevention, and testing behaviors among men who have sex with men--National HIV Behavioral Surveillance System, 21 U.S. cities, United States, 2008.
Finlayson TJ; Le B; Smith A; Bowles K; Cribbin M; Miles I; Oster AM; Martin T; Edwards A; Dinenno E;
MMWR Surveill Summ; 2011 Oct; 60(14):1-34. PubMed ID: 22031280
[TBL] [Abstract][Full Text] [Related]
12. Role of drug injection in the spread of HIV in Argentina and Brazil.
Libonatti O; Lima E; Peruga A; González R; Zacarías F; Weissenbacher M
Int J STD AIDS; 1993; 4(3):135-41. PubMed ID: 8324042
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users.
Spijkerman IJ; van Ameijden EJ; Mientjes GH; Coutinho RA; van den Hoek A
J Clin Epidemiol; 1996 Oct; 49(10):1149-54. PubMed ID: 8826995
[TBL] [Abstract][Full Text] [Related]
14. Gender-specific differences in the natural history, clinical features, and socioeconomic status of HIV-infected patients: experience of a treatment centre in Vienna.
Armbruster C; Kriwanek S; Vorbach H
Wien Klin Wochenschr; 2000 Sep; 112(17):754-60. PubMed ID: 11042904
[TBL] [Abstract][Full Text] [Related]
15. HIV risk behavior among injection drug users in Tehran, Iran.
Razani N; Mohraz M; Kheirandish P; Malekinejad M; Malekafzali H; Mokri A; McFarland W; Rutherford G
Addiction; 2007 Sep; 102(9):1472-82. PubMed ID: 17645427
[TBL] [Abstract][Full Text] [Related]
16. Risk of human immunodeficiency virus type 1-related neurologic disease in a cohort of intravenous drug users.
Marder K; Liu X; Stern Y; Malouf R; Dooneief G; Bell K; Todak G; Joseph M; Sorrell S; el Sadr W
Arch Neurol; 1995 Dec; 52(12):1174-82. PubMed ID: 7492292
[TBL] [Abstract][Full Text] [Related]
17. Gender differences in quality of life outcomes of HIV/AIDS treatment in the latent feminization of HIV epidemics in Vietnam.
Tran BX; Ohinmaa A; Nguyen LT; Oosterhoff P; Vu PX; Vu TV; Larsson M
AIDS Care; 2012; 24(10):1187-96. PubMed ID: 22375681
[TBL] [Abstract][Full Text] [Related]
18. Fatigue in HIV/AIDS is associated with depression and subjective neurocognitive complaints but not neuropsychological functioning.
Millikin CP; Rourke SB; Halman MH; Power C
J Clin Exp Neuropsychol; 2003 Apr; 25(2):201-15. PubMed ID: 12754678
[TBL] [Abstract][Full Text] [Related]
19. AIDS knowledge and attitudes among injection drug users: the issue of reliability.
Longshore D; Hsieh SC; Anglin MD
AIDS Educ Prev; 1992; 4(1):29-40. PubMed ID: 1543642
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting cognitive functioning in a sample of human immunodeficiency virus-positive injection drug users.
Margolin A; Avants SK; Warburton LA; Hawkins KA
AIDS Patient Care STDS; 2002 Jun; 16(6):255-67. PubMed ID: 12133261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
